Dr. Brose on Sorafenib in RAI-Resistant Thyroid Cancer

Marcia Brose, MD, PhD
Published: Sunday, Jun 02, 2013



Marcia Brose, MD, PhD, an assistant professor of otolaryngology and head and neck surgery in the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania, discusses the phase III DECISION study that explored sorafenib in radioactive iodine-resistant differentiated thyroid cancer.

In this study, 417 patients with RAI-resistant metastatic differentiated thyroid cancer were randomized to sorafenib or placebo. The median progression-free survival with sorafenib was 10.8 months compared to 5.8 months in the placebo arm.

Read more about this study >>>

<<< View more from the 2013 ASCO Annual Meeting



Marcia Brose, MD, PhD, an assistant professor of otolaryngology and head and neck surgery in the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania, discusses the phase III DECISION study that explored sorafenib in radioactive iodine-resistant differentiated thyroid cancer.

In this study, 417 patients with RAI-resistant metastatic differentiated thyroid cancer were randomized to sorafenib or placebo. The median progression-free survival with sorafenib was 10.8 months compared to 5.8 months in the placebo arm.

Read more about this study >>>

<<< View more from the 2013 ASCO Annual Meeting


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x